New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Alkermes-plc

More Like This

PR Newswire associated0

New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD)

PR Newswire associated0

Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences

PR Newswire associated0

Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences

PR Newswire associated0

Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan)

PR Newswire associated0

Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences

PR Newswire associated0

Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society

PR Newswire associated1

Groundbreaking pan-European study by Alpharmaxim and Aston University harnesses behavioural science to uncover factors influencing prescribing practice in Parkinson's Disease and identifies clear opportunities to improve treatment options

PR Newswire associated0

New research by Alpharmaxim applies behavioural science to identify and understand prescribing choices in neurogenerative diseases - and highlights the need to optimise them